Last reviewed 2026-04-23 · How we verify

Nerinetide (NA-1)

Nerinetide is a peptide that inhibits postsynaptic density protein 95 (PSD-95) to reduce excitotoxic neuronal death following ischemic stroke.

Nerinetide is a peptide that inhibits postsynaptic density protein 95 (PSD-95) to reduce excitotoxic neuronal death following ischemic stroke. Used for Acute ischemic stroke (within 24 hours of symptom onset).

At a glance

Mechanism of action

Nerinetide blocks the interaction between NMDA receptors and PSD-95, a scaffolding protein that couples excitotoxic calcium influx to downstream neurodegenerative pathways. By uncoupling this signaling without blocking the NMDA receptor itself, the drug preserves beneficial NMDA receptor functions while preventing ischemic neuronal damage. This mechanism is designed to provide neuroprotection in acute ischemic stroke.

Approved indications

• Acute ischemic stroke (within 24 hours of symptom onset)

Common side effects

• Headache
• Nausea
• Hypertension

Key clinical trials

• Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis (PHASE3)
• Field Randomization of Nerinetide (NA-1) Therapy in Early Responders (PHASE3)
• Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Nerinetide (NA-1) CI brief — competitive landscape report
• Nerinetide (NA-1) updates RSS · CI watch RSS
• NoNO Inc. portfolio CI